AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 223 filers reported holding AMICUS THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 1.56 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $185,355 | +21.4% | 15,243 | +25.3% | 0.00% | +50.0% |
| Q2 2023 | $152,742 | +12.7% | 12,161 | -0.5% | 0.00% | 0.0% |
| Q1 2023 | $135,475 | -27.9% | 12,216 | -20.6% | 0.00% | -33.3% |
| Q4 2022 | $187,778 | +16.6% | 15,379 | +0.0% | 0.00% | 0.0% |
| Q3 2022 | $161,000 | +10.3% | 15,378 | +13.4% | 0.00% | 0.0% |
| Q2 2022 | $146,000 | -0.7% | 13,558 | -12.8% | 0.00% | +50.0% |
| Q1 2022 | $147,000 | -6.4% | 15,553 | +14.7% | 0.00% | -33.3% |
| Q4 2021 | $157,000 | +20.8% | 13,558 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $130,000 | -13.3% | 13,558 | -13.1% | 0.00% | 0.0% |
| Q2 2021 | $150,000 | -2.6% | 15,605 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $154,000 | -57.2% | 15,605 | 0.0% | 0.00% | -70.0% |
| Q4 2020 | $360,000 | +35900.0% | 15,605 | +28272.7% | 0.01% | – |
| Q3 2020 | $1,000 | 0.0% | 55 | 0.0% | 0.00% | – |
| Q2 2020 | $1,000 | – | 55 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |